Financial & Business News

Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (“Fate Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that Scott Wolchko, the Company's President and CEO, will retire effective December 31, 2024.

PETACH TIKVA, Israel, Nov. 29, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a written notification (the "Notification Letter") from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is no longer in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market, listing Rule 5550(b)(1), due to its failure to maintain a minimum of $2,500,000 in stockholders' equity. In the Company's Form 6-K dated November 13, 2024, the Company reported stockholders' equity of approximately $2,158,000 as of September 30, 2024.

NESS ZIONA, Israel, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in automotive vision systems, today reported financial results as of and for the third quarter of 2024.

WASHINGTON--(BUSINESS WIRE)--FISCALNOTE RECEIVES CONTINUED LISTING STANDARD NOTICE FROM NYSE.

Technology giant Microsoft (NASDAQ: MSFT) is the center of a major regulatory issue, the outcome of which is likely to impact the company's stock.

The 'Undercovered' Dozen highlights 12 lesser-covered stocks, showcasing diverse investment opportunities and sparking community discussion on their potential. Xinyu Ru sees Argan, Inc. as undervalued with strong growth in gas and renewable energy projects, trading at 21x 1-year forward earnings. AES Corporation's sell-off creates a buying opportunity according to Zenzizenzike Investments due to strong fundamentals and potential upside despite renewable energy subsidy concerns.

SEI (SEIC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Does Priority Technology (PRTH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Reinsurance Group (RGA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Does Virtu Financial (VIRT) have what it takes to be a top stock pick for momentum investors? Let's find out.